BID | 78.60 | ASK | 79.16 | ||
Open | 78.86 | Previous Close | 78.82 | ||
Pre-Market | - | After-Market | 79.04 | ||
- - | - -% |
Target Price | 88.06 | Analyst Rating | Moderate Buy 2.20 | |
Potential % | 11.41 | Finscreener Ranking | ★★+ 46.43 | |
Insiders Trans % 3/6/12 mo. | -/-100/-85 | Value Ranking | ★★★★ 54.84 | |
Insiders Value % 3/6/12 mo. | -/-100/-96 | Growth Ranking | ★★+ 48.16 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-95 | Income Ranking | ★★★+ 47.25 | |
Price Range Ratio 52W % | 44.00 | Earnings Rating | Buy | |
Market Cap | 105.10B | Earnings Date | 21st Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.06 | |
Beta | 0.73 |
Today's Price Range 78.4879.14 | 52W Range 68.8492.02 | 5 Year PE Ratio Range 21.1051.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | -0.05% | ||
1 Month | 7.35% | ||
3 Months | -2.34% | ||
6 Months | -5.72% | ||
1 Year | 2.26% | ||
3 Years | -30.77% | ||
5 Years | -18.10% | ||
10 Years | 40.79% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 6.24 | |||
ROE last 12 Months | 8.97 | |||
ROA (5Y Avg) | 3.45 | |||
ROA last 12 Months | 5.03 | |||
ROC (5Y Avg) | 6.63 | |||
ROC last 12 Months | 6.09 | |||
Return on invested Capital Q | 0.64 | |||
Return on invested Capital Y | 7.18 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 6.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
25.10 | ||||
2.07 | ||||
3.35 | ||||
17.20 | ||||
-198.40 | ||||
4.69 | ||||
-25.66 | ||||
39.00 | ||||
122.75B | ||||
Forward PE | 14.70 | |||
PEG | 4.83 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.20 | ||||
1.80 | ||||
0.29 | ||||
0.51 | ||||
11.00 | ||||
Leverage Ratio | 1.70 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
67.20 | ||||
20.10 | ||||
28.90 | ||||
15.20 | ||||
13.92 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
30.81B | ||||
23.16 | ||||
1.49 | ||||
0.81 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.51 | ||||
2.72 | ||||
6.63 | ||||
7.96 | ||||
Payout ratio | 87.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2024 | 1.18 | 1.25 | 5.93 |
Q01 2024 | 1.11 | 1.20 | 8.11 |
Q04 2023 | 1.56 | 1.57 | 0.64 |
Q03 2023 | 1.26 | 1.30 | 3.17 |
Q02 2023 | 1.28 | 1.30 | 1.56 |
Q01 2023 | 1.12 | 1.13 | 0.89 |
Q04 2022 | 1.56 | 1.52 | -2.56 |
Q03 2022 | 1.36 | 1.37 | 0.74 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
1/2024 QR | 1.26 | 1.61 | Positive |
4/2024 QR | 1.45 | -2.68 | Negative |
4/2024 FY | 5.17 | 0.98 | Positive |
4/2025 FY | 5.44 | -0.37 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 1.18 |
Estimates Count | 14 |
EPS Growth Next 5 Years % | 5.20 |
Volume Overview | |
---|---|
Volume | 5.16M |
Shares Outstanding | 1.33M |
Shares Float | 1.33B |
Trades Count | 50.79K |
Dollar Volume | 407.32M |
Avg. Volume | 6.07M |
Avg. Weekly Volume | 5.13M |
Avg. Monthly Volume | 6.52M |
Avg. Quarterly Volume | 6.57M |
Medtronic plc. (NYSE: MDT) stock closed at 78.82 per share at the end of the most recent trading day (a -1.18% change compared to the prior day closing price) with a volume of 4.77M shares and market capitalization of 105.10B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 90000 people. Medtronic plc. CEO is Geoffrey S. Martha.
The one-year performance of Medtronic plc. stock is 2.26%, while year-to-date (YTD) performance is 1.42%. MDT stock has a five-year performance of -18.1%. Its 52-week range is between 68.84 and 92.02, which gives MDT stock a 52-week price range ratio of 44.00%
Medtronic plc. currently has a PE ratio of 25.10, a price-to-book (PB) ratio of 2.07, a price-to-sale (PS) ratio of 3.35, a price to cashflow ratio of 17.20, a PEG ratio of 4.83, a ROA of 5.03%, a ROC of 6.09% and a ROE of 8.97%. The company’s profit margin is 13.92%, its EBITDA margin is 28.90%, and its revenue ttm is $30.81 Billion , which makes it $23.16 revenue per share.
Of the last four earnings reports from Medtronic plc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.18 for the next earnings report. Medtronic plc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Medtronic plc. is Moderate Buy (2.2), with a target price of $88.06, which is +11.41% compared to the current price. The earnings rating for Medtronic plc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Medtronic plc. has a dividend yield of 3.51% with a dividend per share of $2.72 and a payout ratio of 87.00%.
Medtronic plc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 5.57, ATR14 : 1.34, CCI20 : 68.60, Chaikin Money Flow : 0.11, MACD : 1.63, Money Flow Index : 82.58, ROC : 5.26, RSI : 63.05, STOCH (14,3) : 81.05, STOCH RSI : 0.00, UO : 59.27, Williams %R : -18.95), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Medtronic plc. in the last 12-months were: Rob Ten Hoedt (Option Excercise at a value of $305 034), Sean Salmon (Option Excercise at a value of $920 027), Sean Salmon (Sold 16 631 shares of value $1 338 735 ), Wall Brett (Option Excercise at a value of $0), Wall Brett (Sold 1 000 shares of value $83 380 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
CEO: Geoffrey S. Martha
Telephone: +353 14381700
Address: Lower Hatch Street, Dublin 2, , IE
Number of employees: 90 000
Mon, 27 Nov 2023 10:40 GMT Analysts Top Healthcare Picks: Medtronic (MDT), Sanofi (SNYNF)
- TipRanks. All rights reserved.Fri, 29 Sep 2023 15:40 GMT Carlyle in talks to acquire two Medtronic units for over $7B, Reuters says
- TipRanks. All rights reserved.Tue, 22 Aug 2023 13:40 GMT Unusually active option classes on open August 22nd
- TipRanks. All rights reserved.Mon, 24 Jul 2023 02:25 GMT Medtronic (MDT) Gets a Hold from Truist Financial
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.